Chagas disease: Difference between revisions

Jump to navigation Jump to search
No edit summary
 
(52 intermediate revisions by 11 users not shown)
Line 1: Line 1:
__NOTOC__
{{featured article}}
{{featured article}}
{{Infobox_Disease |
{{Infobox_Disease |
Line 4: Line 5:
  Image = Trypanosoma cruzi crithidia.jpeg |
  Image = Trypanosoma cruzi crithidia.jpeg |
  Caption = Photomicrograph of [[Giemsa]]-stained ''Trypanosoma cruzi'' [[crithidia]] ([[Centers for Disease Control and Prevention|CDC]]) |
  Caption = Photomicrograph of [[Giemsa]]-stained ''Trypanosoma cruzi'' [[crithidia]] ([[Centers for Disease Control and Prevention|CDC]]) |
DiseasesDB = 13415 |
ICD10 = {{ICD10|B|57||b|50}} |
ICD9 = {{ICD9|086}} |
ICDO = |
OMIM = |
MedlinePlus = 001372 |
eMedicineSubj =|
eMedicineTopic =|
MeshID = D014355 |
}}
}}
{{Chagas disease}}
'''For patient information click [[{{PAGENAME}} (patient information)|here]]'''
'''For patient information click [[{{PAGENAME}} (patient information)|here]]'''


{{Chagas disease}}
{{CMG}}; {{AE}} {{YD}}, {{Hudakarman}} {{RT}}, {{Tamar}}
{{CMG}}
 
{{SK}} Chagas' disease; American trypanosomiasis; Trypanosoma cruzi infection


==[[Chagas disease overview|Overview]]==
==[[Chagas disease overview|Overview]]==


==[[Chagas disease historical perspective|Historical Perspective]]==
==[[Chagas disease historical perspective|Historical Perspective]]==
==[[Chagas disease classification|Classification]]==


==[[Chagas disease pathophysiology|Pathophysiology]]==
==[[Chagas disease pathophysiology|Pathophysiology]]==
==[[Chagas disease epidemiology and demographics|Epidemiology & Demographics]]==
==[[Chagas disease risk factors|Risk Factors]]==
==[[Chagas disease screening|Screening]]==


==[[Chagas disease causes|Causes]]==
==[[Chagas disease causes|Causes]]==


==[[Chagas disease differential diagnosis|Differentiating Chagas disease]]==
==[[Chagas disease differentiating chagas disease from other diseases|Differentiating Chagas disease from other Diseases]]==


==[[Chagas disease natural history|Complications & Prognosis]]==
==[[Chagas disease epidemiology and demographics|Epidemiology and Demographics]]==


==Diagnosis==
==[[Chagas disease risk factors|Risk Factors]]==
[[Chagas disease history and symptoms|History and Symptoms]] | [[Chagas disease physical examination|Physical Examination]] | [[Chagas disease staging|Staging]] | [[Chagas disease laboratory tests|Laboratory tests]] | [[Chagas disease electrocardiogram|Electrocardiogram]]  | [[Chagas disease x ray|X Rays]] | [[Chagas disease CT|CT]] | [[Chagas disease MRI|MRI]] [[Chagas disease echocardiography or ultrasound|Echocardiography or Ultrasound]] | [[Chagas disease other imaging findings|Other images]] | [[Chagas disease other diagnostic studies|Alternative diagnostics]]
 
==Treatment==
[[Chagas disease medical therapy|Medical therapy]] | [[Chagas disease surgery|Surgical options]] | [[Chagas disease primary prevention|Primary prevention]]  | [[Chagas disease secondary prevention|Secondary prevention]] | [[Chagas disease cost-effectiveness of therapy|Financial costs]] | [[Chagas disease future or investigational therapies|Future therapies]]
==Infection cycle==
An infected triatomine insect vector feeds on blood and releases trypomastigotes in its feces near the site of the bite wound. The victim, by scratching the site of the bite, causes trypomastigotes to enter the host through the wound, or through intact mucosal membranes, such as the [[conjunctiva]]. Then, inside the host, the trypomastigotes invade cells, where they differentiate into intracellular [[amastigote]]s. The amastigotes multiply by [[binary fission]] and differentiate into trypomastigotes, then are released into the circulation as bloodstream trypomastigotes. These trypomastigotes infect cells from a variety of [[biological tissue]]s and transform into intracellular amastigotes in new infection sites. Clinical manifestations and cell death at the target tissues can occur because of this infective cycle. For example, it has been shown by Austrian-Brazilian pathologist Dr. [[Fritz Köberle]] in the 1950s at the [[Faculdade de Medicina de Ribeirão Preto|Medical School of the University of São Paulo at Ribeirão Preto]], Brazil, that intracellular amastigotes destroy the intramural neurons of the [[autonomic nervous system]] in the intestine and heart, leading to megaintestine and heart [[aneurysm]]s, respectively.
 
The bloodstream trypomastigotes do not replicate (unlike the African [[trypanosomes]]). Replication resumes only when the parasites enter another cell or are ingested by another vector. The “kissing” bug becomes infected by feeding on human or animal blood that contains circulating parasites. Moreover the bugs might be able to spread the infection to each other through their cannibalistic predatory behaviour. The ingested trypomastigotes transform into epimastigotes in the vector’s midgut. The parasites multiply and differentiate in the midgut and differentiate into infective metacyclic trypomastigotes in the hindgut.
 
''[[Trypanosoma cruzi]]'' can also be transmitted through [[blood transfusions]], organ [[transplantation]], [[placenta|transplacentally]], [[breast milk]],<ref>Santos Ferreira C, Amato Neto V, Gakiya E, ''et al.'' "Microwave treatment of human milk to prevent transmission of Chagas disease." Rev Inst Med Trop São Paulo. 2003 Jan-Feb;45(1):41-2. PMID 12751321</ref> and in laboratory accidents. According to the [[World Health Organization]], the infection rate in Latin American [[blood bank]]s varies between 3% and 53%, a figure higher than of [[HIV]] infection and [[hepatitis]] B and C.<ref name=WHO>WHO. [http://www.who.int/tdr/diseases/chagas/ Chagas.] Accessed 24 September 2006.</ref>
 
Children can also acquire Chagas' Disease while still in the womb. Chagas' disease accounts for approximately 13% of stillborn deaths in parts of Brazil. It is recommended that pregnant women be tested for the disease.<ref>Hudson L, Turner MJ. "Immunological Consequences of Infection and Vaccination in South American Trypanosomiasis [and Discussion]". Philosophical Transactions of the Royal Society of London. Series B, Biological Sciences, Vol. 307, No. 1131, Towards the Immunological Control of Human Protozoal Diseases. (November 13, 1984), pp. 51–61. JSTOR. Accessed 2/22/07. PMID 6151688 </ref>
 
[[Image:Trypanosoma cruzi LifeCycle.gif|Life cycle of [[Trypanosima cruzi]]. Source: CDC]]
 
===Alternative infection mechanism===
Researchers suspected since 1991 that the transmission of the trypanosome by the oral route might be possible,<ref>Shikanai-Yasuda MA, Marcondes CB, Guedes LA, ''et al.'' "Possible oral transmission of acute Chagas disease in Brazil." Rev Inst Med Trop São Paulo. 1991 Sep-Oct;33(5):351-7. PMID 1844961</ref> due to a number of micro-epidemics restricted to particular times and places (such as a farm or a family dwelling), particularly in non-endemic areas such as the Amazonia (17 such episodes recorded between 1968 and 1997). In 1991, farm workers in the state of Paraíba, Brazil, were apparently infected by contamination of food with opossum feces; and in 1997, in Macapá, state of Amapá, 17 members of two families were probably infected by drinking acai palm fruit juice contaminated with crushed triatomine vector insects.<ref>da Silva Valente S, de Costa Valente V, Neto H. "Considerations on the epidemiology and transmission of Chagas disease in the Brazilian Amazon." Mem Inst Oswaldo Cruz 94 Suppl 1: 395-8. PMID 10677763</ref> In the beginning of 2005, a new outbreak with 27 cases was detected in Amapá. Despite many warnings in the press and by health authorities, this source of infection continues unabated. In August 2007 the Ministry of Health released the information that in the previous one year and half 15 clusters of Chagas infection in 116 people via ingestion of assai have been detected in the Amazon region <ref>[http://www1.folha.uol.com.br/fsp/cotidian/ff1808200701.htm Açaí faz 1 vítima de Chagas a cada 4 dias na Amazônia. ''Jornal Folha de São Paulo''] </ref>
 
In March 2005, a new startling outbreak was recorded in the state of Santa Catarina, Brazil, that seemed to confirm this alternative mechanism of transmission. Several people in Santa Catarina who had ingested sugar cane juice ("garapa", in Portuguese) by a roadside kiosk acquired Chagas' disease.<ref>UK Health Protection Agency (HPA).[http://www.hpa.org.uk/cdr/archives/archive05/News/news1305.htm Chagas’ disease (American trypanosomiasis) in southern Brazil.] Accessed 24 September 2006.</ref> As of March 30, 2005, 49 cases had been confirmed in Santa Catarina, including 6 deaths.<!--http://aol.countrywatch.com/aol_wire.asp?vCOUNTRY=183&UID=1442449 This is not an acceptable source, it is only available on AOL - please provide general URL or information accessible to all. --> The hypothesized mechanism, so far, is that trypanosome-bearing insects were crushed into the raw preparation. The health authorities of Santa Catarina have estimated that ca. 60,000 people might have had contact with the contaminated food in Santa Catarina and urged everyone in this situation to submit to blood tests. They have prohibited the sale of sugar cane juice in the state until the situation is rectified.
 
The unusual severity of the disease outbreak has been blamed on a hypothetical higher parasite load achieved by the oral route of infection. Brazilian researchers at the Instituto Oswaldo Cruz, Rio de Janeiro, were able to infect mice via a gastrointestinal tube with trypanosome-infected oral preparations.
 
People also can become infected through:
 
*Consumption of uncooked food contaminated with feces from infected bugs.
*Congenital transmission (from a pregnant woman to her baby).
*Blood transfusion.
*Organ transplantation.
*Accidental laboratory exposure.
 
It is generally considered safe to breastfeed even if the mother has Chagas disease. However, if the mother has cracked nipples or blood in the breast milk, she should pump and discard the milk until the nipples heal and the bleeding resolves.
 
Chagas disease is not transmitted from person-to-person like a cold or the flu or through casual contact.
 
==Laboratory diagnosis==
Diagnosis of chronic Chagas disease is made after consideration of the patient's clinical findings, as well as by the likelihood of being infected, such as having lived in an endemic country. Diagnosis is generally made by testing with at least two different serologic tests.
 
Demonstration of the causal agent is the diagnostic procedure in acute Chagas' disease. It almost always yields positive results, and can be achieved by:
[[Image:T. cruzi.jpg|right|thumb|Trypanosoma cruzi in blood smears, Giemsa stain.]]
[[Image:T.cruzi .jpg|right|thumb|Trypanosoma cruzi in blood smears, Giemsa stain.]]
* [[microscope|Microscopic]] examination: a) of fresh anticoagulated [[blood]], or its [[buffy coat]], for motile parasites; and b) of thin and thick blood smears stained with [[Giemsa stain|Giemsa]], for visualization of [[parasites]]; it can be confused with the 50% longer ''[[Trypanosoma rangeli]]'', which has not shown any pathogenicity in humans yet.
* Isolation of the agent by: a) inoculation into mice; b) culture in specialized media (e.g., NNN, LIT); and c) xenodiagnosis, where uninfected [[Reduviidae]] bugs are fed on the patient's blood, and their gut contents examined for parasites 4 weeks later.
*Various Immunodiagnostic tests; (also trying to distinguish [[Strain (biology)|strains]] (zymodemes) of ''T.cruzi'' with divergent pathogenicities).
**[[Complement fixation]]
**indirect [[hemagglutination]]
**IFA, Indirect fluorescent assay
**[[Radioimmunoassay|RIA]], Radio-immunoassay
**[[ELISA]], Enzyme-Linked Immunosorbent Assay
*Diagnosis based on [[Molecular Biology]] techniques.
**[[PCR]], Polymerase chain reaction, most promising
 
''Antibody Detection:''
[[Image:Positive IFA result.jpg|right|thumb|Positive IFA result]]
Infections with Trypanosoma cruzi are common in Mexico, Central America, and South America.  Many immigrants from areas where Chagas disease is endemic currently reside in the United States and are potential sources for parasite transmission via contaminated blood.  During the acute phase of illness, blood film examination generally reveals the presence of trypomastigotes.  During the chronic phase of infection, parasitemia is low; immunodiagnosis is a useful technique for determining whether the patient is infected.
 
The indirect fluorescent antibody (IFA) test is available at CDC.  IFA antigen slides are prepared from a suspension of epimastigotes.  Although IFA is very sensitive, cross-reactivity can occur with sera from patients with leishmaniasis, a protozoan disease that occurs in some of the same geographical areas as T. cruzi.  Various serologic methods are commercially available in the U.S. and other countries for laboratory diagnosis of Chagas disease.  The sensitivity and specificity of these tests are highly variable.
 
==Prognosis==
An index for classification of patients who have Chagas' disease was published in the August 24, 2006 edition of the ''[[New England Journal of Medicine]]''.<ref>{{cite journal | author = Rassi A Jr, Rassi A, Little W, Xavier S, Rassi S, Rassi A, Rassi G, Hasslocher-Moreno A, Sousa A, Scanavacca M | title = Development and validation of a risk score for predicting death in Chagas' heart disease | journal = N Engl J Med | volume = 355 | issue = 8 | pages = 799–808 | year = 2006 | id = PMID 16928995}}</ref> Based on over 500 patients, this index includes clinical aspects, [[X-ray]] findings, [[Electrocardiogram|EKG]], [[echocardiography]] and [[Holter monitor|Holter]].
 
{|border="1" cellpadding="5" cellspacing="0"
|+ '''Chagas' risk factors'''
|-
!style="background:#efefef;" |Risk factor!!style="background:#efefef;"|points
|-
|[[New York Heart Association Functional Classification|NYHA class]] III or IV||5
|-
|[[Cardiomegaly]]||5
|-
|Wall motion abnormalities||3
|-
|non-sustained [[ventricular tachycardia]]||3
|-
|low voltage on [[electrocardiogram|ECG]]||2
|-
|male sex||2
|}
 
{|border="1" cellpadding="5" cellspacing="0"
|- style="background:#efefef;"
!Total points!!Risk of death in 10 years
|-
|0–6||10%
|-
|7–11||40%
|-
|12–20||85%
|}
 
==Treatment==
There are two approaches to therapy, both of which can be life saving:
 
*'''antiparasitic treatment''', to kill the parasite; and
*'''symptomatic treatment''', to manage the symptoms and signs of infection.
 
Medication for Chagas' disease is usually only effective when given during the [[Acute (medical)|acute]] stage of infection. The drugs of choice are azole or nitroderivatives such as [[benznidazole]]<ref>Garcia S, Ramos CO, Senra JF, ''et al.'' "Treatment with benznidazole during the chronic phase of experimental Chagas disease decreases cardiac alterations." Antimicrob Agents Chemother. 2005 Apr;49(4):1521–8. PMID 15793134 [http://aac.asm.org/cgi/content/abstract/49/4/1521 Online]</ref> or [[nifurtimox]] (under an Investigational New Drug protocol from the [[Centers for Disease Control and Prevention|CDC]] Drug Service), but resistance to these drugs has already been reported.<ref>Buckner FS, Wilson AJ, White TC, Van Voorhis WC. "Induction of resistance to azole drugs in Trypanosoma cruzi." Antimicrob Agents Chemother. 1998 Dec;42(12):3245–50. PMID 9835521 [http://aac.asm.org/cgi/content/abstract/42/12/3245 Online]</ref> Furthermore, these agents are very toxic and have many [[adverse effect (medicine)|adverse effects]], and cannot be taken without medical supervision. The antifungal agent [[Amphotericin B]] has been proposed as a second-line drug, but cost and this drug's relatively high toxicity have limited its use. Moreover, 10-year study of chronic administration of drugs in Brazil has revealed that current chemotherapy does not totally remove [[parasitemia]].<ref>Lauria-Pires L, Braga MS, Vexenat AC, ''et al.'' "Progressive chronic Chagas heart disease ten years after treatment with anti-Trypanosoma cruzi nitroderivatives." Am J Trop Med Hyg. 2000 Sep-Oct;63(3-4):111-8. PMID 11388500 [http://www.ajtmh.org/cgi/reprint/63/3/111.pdf PDF Full text]</ref> Thus, the decision about whether to use [[antiparasitic]] therapy should be individualized in consultation with an expert.
 
In the [[chronic (medicine)|chronic]] stage, treatment involves managing the clinical manifestations of the disease, e.g., drugs and [[heart pacemaker]] for [[chronic heart failure]] and [[heart arryhthmia]]s; [[surgery]] for megaintestine, etc., but the disease per se is not curable in this phase. Chronic heart disease caused by Chagas' disease is now a common reason for [[heart transplantation]] surgery. Until recently, however, Chagas' disease was considered a [[contraindication]] for the procedure, since the heart damage could recur as the parasite was expected to seize the opportunity provided by the [[immunosuppression]] that follows surgery. The research that changed the indication of the transplant procedure for Chagas' disease patients was conducted by Dr. [[Adib Jatene]]'s group at the Heart Institute of the University of São Paulo, in São Paulo, Brazil.<ref>Bocchi EA, Bellotti G, Mocelin AO, Uip D, ''et al.'' "Heart transplantation for chronic Chagas' heart disease." Ann Thorac Surg. 1996 Jun;61(6):1727–33. PMID 8651775[http://ats.ctsnetjournals.org/cgi/content/abstract/61/6/1727 Online]</ref> The research noted that survival rates in Chagas' patients can be significantly improved by using lower dosages of the immunosuppressant drug [[cyclosporin]]. Recently, direct [[stem cell therapy]] of the heart muscle using [[bone marrow]] cell transplantation has been shown to dramatically reduce risks of heart failure in Chagas patients.<ref>Vilas-Boas F, Feitosa GS, Soares MB, Mota A, ''et al.'' "[Early results of bone marrow cell transplantation to the myocardium of patients with heart failure due to Chagas disease]." Arq Bras Cardiol. 2006 Aug;87(2):159-66. PMID 16951834 [http://publicacoes.cardiol.br/abc/2004/8202/8202010i.pdf PDF Full text.] [http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0066-782X2004000200010&tlng=en&lng=en&nrm=iso Also available here.]</ref> Patients have also been shown to benefit from the strict prevention of reinfection, though the reason for this is not yet clearly understood.
 
Some examples for the struggle for advances:
*Use of oxidosqualene cyclase inhibitors and [[cysteine protease]] inhibitors has been found to cure experimental infections in animals.<ref>Engel JC, Doyle PS, Hsieh I, McKerrow JH. "Cysteine protease inhibitors cure an experimental Trypanosoma cruzi infection." J Exp Med. 1998 August 17;188(4):725-34. PMID 9705954[http://www.jem.org/cgi/content/abstract/188/4/725 Online.]</ref>
*[[Dermaseptin]]s from frog species ''Phyllomedusa oreades'' and ''P. distincta''. Anti-''Trypanosoma cruzi ''activity without [[cytotoxicity]] to mammalian cells.<ref>PMID 12379643</ref>
*Design of inhibitors to enzymes involved in [[trypanothione]] metabolism, which is unique to the kinetoplastid group of parasites.<ref>Fairlamb AH, Cerami A. "Metabolism and functions of trypanothione in the Kinetoplastida." Annu Rev Microbiol. 1992;46:695–729. PMID 1444271</ref>
*The sesquiterpene lactone dehydroleucodine (DhL) affects the growth of cultured epimastigotes of ''Trypanosoma cruzi''<ref>Brengio SD, Belmonte SA, Guerreiro E, ''et al.'' "The sesquiterpene lactone dehydroleucodine (DhL) affects the growth of cultured epimastigotes of Trypanosoma cruzi." J Parasitol. 2000 Apr;86(2):407-12. PMID 10780563</ref>
* The [[genome]] of Trypanosoma cruzi has been sequenced.<ref>El-Sayed NM, Myler PJ, Bartholomeu DC, ''et al.'' (2005). "The genome sequence of Trypanosoma cruzi, etiologic agent of Chagas disease". Science 309 (5733): 409-15. PMID 16020725</ref> Proteins that are produced by the disease but not by humans have been identified as possible drug targets to defeat the disease.<ref>El-Sayed, ''et al.'', 2005</ref>
 
==Prevention==
[[Image:Triatoma infestans.jpg|thumb|Vector insect ''[[Triatoma infestans]]'' (Kissing Bug)]]
A reasonably effective [[vaccine]] was developed in Ribeirão Preto in the 1970s, using cellular and subcellular fractions of the parasite, but it was found economically unfeasible. More recently, the potential of DNA vaccines for [[immunotherapy]] of acute and chronic Chagas' disease is being tested by several research groups.
 
Prevention is centered on fighting the vector (''Triatoma'') by using sprays and paints containing [[insecticide]]s (synthetic [[pyrethrum|pyrethroids]]), and improving housing and sanitary conditions in the rural area. For urban dwellers, spending vacations and camping out in the wilderness or sleeping at hostels or mud houses in endemic areas can be dangerous, a [[mosquito net]] is recommended. If the traveller intends to travel to the area of prevalence, he/she should get information on endemic rural areas for Chagas' disease in traveller advisories, such as the [[Centers for Disease Control and Prevention|CDC]].
 
In most countries where Chagas' disease is endemic, [[blood tests|testing]] of [[blood donation|blood donors]] is already mandatory, since this can be an important route of transmission. The United States FDA has recently licensed a test for antibodies against T. cruzi for use on blood donors but has not yet mandated its use.  The AABB recommends that past recipients of blood components from donors found to be infected be notified and themselves tested. 
In the past, donated blood was mixed with 0,25 g/L of [[gentian violet]] successfully to kill the parasites. Early detection and treatment of new cases, including mother-to-baby cases, will also help reduce the burden of disease.
 
With all these measures, some landmarks were achieved in the fight against Chagas' disease in Latin America: a reduction by 72% of the incidence of human infection in children and young adults in the countries of the Initiative of the Southern Cone, and at least two countries (Uruguay, in 1997, and Chile, in 1999), were certified free of vectorial and transfusional transmission. In Brazil, with the largest population at risk, 10 out of the 12 endemic states were also certified free.


Some stepstones of vector control:
=[[Chagas disease screening|Screening]]==
*A yeast trap has been tested for monitoring infestations of certain species of the bugs:"Performance of yeast-baited traps with ''Triatoma sordida'', ''Triatoma brasiliensis'', ''Triatoma pseudomaculata'', and ''Panstrongylus megistus'' in laboratory assays."<ref>Pires HH, Lazzari CR, Diotaiuti L, Lorenzo MG. "Performance of yeast-baited traps with Triatoma sordida, Triatoma brasiliensis, Triatoma pseudomaculata, and Panstrongylus megistus in laboratory assays." Rev Panam Salud Publica. 2000 Jun;7(6):384-8. PMID 10949899</ref>
*Promising results were gained with the treatment of vector habitats with the fungus ''[[Beauveria bassiana]]'', (which is also in discussion for [[malaria]]- prevention):"Activity of oil-formulated ''Beauveria bassiana'' against ''Triatoma sordida'' in peridomestic areas in Central Brazil."<ref>Luz C, Rocha LF, Nery GV, Magalhaes BP, Tigano MS. "Activity of oil-formulated Beauveria bassiana against Triatoma sordida in peridomestic areas in Central Brazil." Mem Inst Oswaldo Cruz. 2004 Mar;99(2):211-8. PMID 15250478 [http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0074-02762004000200017&tlng=es&lng=en&nrm=iso Online.]</ref>
*Targeting the [[symbiont]]s of [[Triatominae]] through [[paratransgenesis]].<ref>{{cite web|url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Search&db=PubMed&term=Triatominae%20symbiosis|title=PubMed Search on Triatominae symbiosis}}</ref>


==See also==
==[[Chagas disease natural history, complications and prognosis|Natural History, Complications and Prognosis]]==
*[[Tropical disease]]
*[[Drugs for Neglected Diseases Initiative]]
* Distinguish from: [[Chaga mushroom]]


==Notes==
==[[Diagnosis]]==
<!--This article uses the Cite.php citation mechanism. If you would like more information on how to add references to this article, please see http://meta.wikimedia.org/wiki/Cite/Cite.php -->
<div class="references-small" style="-moz-column-count:2; column-count:2;">
<references/>
</div>


==References==
[[Chagas disease diagnostic criteria|Diagnostic Criteria]] | [[Chagas disease history and symptoms|History and Symptoms]] | [[Chagas disease physical examination | Physical Examination]] | [[Chagas disease laboratory findings | Laboratory findings]] | [[Chagas disease electrocardiogram | Electrocardiogram]] | [[Chagas disease x ray|X-ray]] | [[Chagas disease electrocardiogram | Electrocardiogram]] | [[Chagas disease  echocardiography and ultrasound|Echocardiography and Ultrasound]] |[[Chagas disease CT scan | CT scan]] | [[Chagas disease MRI | MRI]] | [[Chagas disease other imaging findings|Other Imaging Findings]] | [[Chagas disease other diagnostic studies|Other diagnostic studies]]
* CDC, Division of Parasitic Diseases. [http://www.cdc.gov/NCIDOD/DPD/PARASITES/chagasdisease/factsht_chagas_disease.htm Chagas Disease Fact Sheet.] (23 September 2004). Accessed 24 September 2006.
* {{cite journal | author=Dumonteil E, Escobedo-Ortegon J, Reyes-Rodriguez N, Arjona-Torres A, Ramirez-Sierra M | title=Immunotherapy of Trypanosoma cruzi infection with DNA vaccines in mice. | journal=Infect Immun | volume=72 | issue=1 | pages=46–53 | year=2004 | id=PMID 14688079}}
* CDC, Division of Parasitic Diseases.[http://www.cdc.gov/ncidod/dpd/parasites/chagasdisease/disease_chagas_disease.htm Chagas Disease](23 October 2007). Accessed 16 August 2007.
* CDC, Division of Parasitic Diseases.[http://www.cdc.gov/ncidod/dpd/parasites/chagasdisease/epidemiology_chagas_disease.htm Chagas Disease Epidemiology.](23 October 2007). Accessed 16 August 2007.
*CDC, Division of Parasitic Diseases. [http://www.cdc.gov/ncidod/dpd/parasites/chagasdisease/treatment_chagas_disease.htm Treatment](23 October 2007). Accessed 16 August 2007.


==Further reading==
==[[Treatment]]==
<div class="references-small">
* {{cite journal | author=Coutinho M | title=Ninety years of Chagas disease: a success story at the periphery. | journal=Soc Stud Sci | volume=29 | issue=4 | pages=519-49 | year=1999 | id=PMID 11623933}}
* {{cite journal | author=Dias J, Silveira A, Schofield C | title=The impact of Chagas disease control in Latin America: a review. | journal=Mem Inst Oswaldo Cruz | volume=97 | issue=5 | pages=603-12 | year=2002 | id=PMID 12219120 | url=http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0074-02762002000500002&tlng=es&lng=en&nrm=iso}}
* {{cite journal | author=Kropf S, Azevedo N, Ferreira L | title=Biomedical research and public health in Brazil: the case of Chagas' disease (1909–50). | journal=Soc Hist Med | volume=16 | issue=1 | pages=111-29 | year=2003 | id=PMID 14598820}}
* {{cite journal | year = 1999 | title = International Symposium to commemorate the 90th anniversary of the discovery of Chagas disease (Rio de Janeiro, April 11–16, 1999) | journal = Memorias do Instituto Oswaldo Cruz | volume = 94 | issue = Suppl. I | url =http://www.dbbm.fiocruz.br/tropical/chagas/memmain.html}}
* {{cite journal | author=Moncayo A | title=Progress towards interruption of transmission of Chagas disease. | journal=Mem Inst Oswaldo Cruz | volume=94 Suppl 1 | pages=401-4 | id=PMID 10677765 | url=http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0074-02761999000700079&lng=en&nrm=iso}}
* {{cite journal | author=Prata A | title=Evolution of the clinical and epidemiological knowledge about Chagas disease 90 years after its discovery. | journal=Mem Inst Oswaldo Cruz | volume=94 Suppl 1 | pages=81-8 | id=PMID 10677694 | url=http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0074-02761999000700008&lng=en&nrm=iso}}
* {{cite journal | author=Franco-Paredes C | title=Chagas disease: an impediment in achieving the Millennium Development Goals in Latin America. | journal=BMC International Health and Human Rights | volume=7 | pages=7 | year=2007 | id=PMID 17725836 | url=http://http://www.biomedcentral.com/1472-698X/7/7/abstract}}
* {{cite book | editor = Kevin M. Tyler & Michael A. Miles | title = World Class Parasites. Volume 7: American Trypanosomiasis | publisher = Kluwer Academic Publishers | id = ISBN 1-4020-7323-2}} [http://www.amazon.com/dp/1402073232/ Amazon review]
</div>


==External links==
[[Chagas disease medical therapy|Medical Therapy]] | [[Chagas disease surgery|Surgery]] | [[Chagas disease primary prevention|Primary Prevention]] | [[Chagas disease secondary prevention|Secondary Prevention]] | [[Chagas disease cost-effectiveness of therapy|Cost-Effectiveness of Therapy]] | [[Chagas disease future or investigational therapies|Future or Investigational Therapies]]
* [http://www.vcu.edu/csbc/vpp/ VCU Virtual Parasite Project]
* [http://www.allaboutchagasdisease.com''All About Chagas Disease''], Chagas' disease Information & Prevention, Identification, also in Spanish.
* [http://chagaspace.org/eng/index.htm ''Chagaspace''], also in Spanish.
* [http://www.unibio.unam.mx/chagmex ChagMex: Database on-line]. UNAM-Instituto de Biología.
* [http://www.paho.org/english/ad/dpc/cd/chagas.htm Chagas Disease]. PanAmerican Health Organization.
* [http://www.phac-aspc.gc.ca/tmp-pmv/info/am_trypan_e.html Disease Information. American Trypanosomiasis or Chagas' Disease]. Travel Medicine Program. Health Canada.
* [http://www.lib.uiowa.edu/hardin/md/trypanosomiasisAmer.html Links to Chagas' Disease pictures (Hardin MD/Univ of Iowa)]
* [http://www.uta.edu/chagas Link to "The Kiss of Death"]. An anthropological view of Chagas' disease (Joseph Bastien/Univ of Texas at Arlington).


===Recent news and events===
==Case Studies==
* [http://www.pe.com/localnews/rivcounty/stories/PE_News_Local_S_blood18.3d5c374.html/ Chagas' disease parasite found in desert blood samples]
[[Chagas disease case study one|Case #1]]
* ''Chagas Control in the Southern Cone Countries: History of an International Initiative, 1991/2001'', PAHO. ([http://www.paho.org/English/AD/DPC/CD/dch-historia-incosur.htm Full text e-book])
* [http://cruzi.unsam.edu.ar/ Genome Sequencing Project]
* [http://news.bbc.co.uk/2/hi/health/4681707.stm Parasites' genetic code 'cracked'] From BBC
*Catholic Relief Services. [http://www.crs.org/our_work/where_we_work/overseas/latin_america_and_the_caribbean/bolivia/improvement.cfm Housing Improvement and Chagas' Disease Prevention Project]
*2006: [http://www.nature.com/nature/journal/v440/n7081/full/440153a.html Nature.com / Scott M. Landfear: ''Flagella are whip-like structures that power the movement of certain cells. Analysis of a single-cell parasite, the African trypanosome, reveals that flagella are also essential for viability in this organism.''] (restricted commercial access now)
*[http://www.sciencemag.org/cgi/search?fulltext=chagas&collection_num=MEDICINE&collections_search_keyword_go.x=0&collections_search_keyword_go.y=0 Science Magazine Search Results: ''Chagas'']


{{Protozoal diseases}}
{{Protozoal diseases}}
{{Link FA|pl}}
[[ar:شاجاس]]
[[ca:Malaltia de Chagas]]
[[de:Chagas-Krankheit]]
[[es:Enfermedad de Chagas]]
[[fr:Maladie de Chagas]]
[[it:Malattia di Chagas]]
[[lt:Čagaso liga]]
[[ms:Penyakit Cagas]]
[[nl:Ziekte van Chagas]]
[[ja:シャーガス病]]
[[pt:Doença de Chagas]]
[[sv:Chagas sjukdom]]
[[pl:Choroba Chagasa]]


{{WikiDoc Help Menu}}
{{WikiDoc Help Menu}}
{{WikiDoc Sources}}
{{WikiDoc Sources}}


[[Category:Parasitic diseases]]
[[Category:Zoonoses]]
[[Category:Tropical disease]]
[[Category:Neglected diseases]]
[[Category:Insect-borne diseases]]
[[Category:Disease]]
[[Category:Disease]]
[[Category:Up-To-Date]]
[[Category:Neurology]]
[[Category:Emergency medicine]]
[[Category:Infectious disease]]
[[Category:Infectious disease]]
[[Category:Mature chapter]]
[[Category:Gastroenterology]]
[[Category:Overview complete]]
[[Category:Cardiology]]

Latest revision as of 23:25, 15 October 2020

Template:Featured article

Chagas disease
Photomicrograph of Giemsa-stained Trypanosoma cruzi crithidia (CDC)

Chagas disease Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Chagas disease from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Criteria

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

X-ray

Echocardiography and Ultrasound

CT scan

MRI

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Chagas disease On the Web

Most recent articles

cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Chagas disease

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Chagas disease

CDC on Chagas disease

Chagas disease in the news

Blogs on Chagas disease

Directions to Hospitals Treating Chagas disease

Risk calculators and risk factors for Chagas disease

For patient information click here

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Yazan Daaboul, M.D., Huda A. Karman, M.D. Raviteja Guddeti, M.B.B.S. [2], Tamar Sifri [3]

Synonyms and keywords: Chagas' disease; American trypanosomiasis; Trypanosoma cruzi infection

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Chagas disease from other Diseases

Epidemiology and Demographics

Risk Factors

Screening=

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Criteria | History and Symptoms | Physical Examination | Laboratory findings | Electrocardiogram | X-ray | Electrocardiogram | Echocardiography and Ultrasound | CT scan | MRI | Other Imaging Findings | Other diagnostic studies

Treatment

Medical Therapy | Surgery | Primary Prevention | Secondary Prevention | Cost-Effectiveness of Therapy | Future or Investigational Therapies

Case Studies

Case #1

Template:Protozoal diseases


Template:WikiDoc Sources